160 related articles for article (PubMed ID: 37067735)
1. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
[TBL] [Abstract][Full Text] [Related]
2. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
3. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.
Lin P; Gao RZ; Wen R; He Y; Yang H
Front Immunol; 2021; 12():715460. PubMed ID: 34456923
[TBL] [Abstract][Full Text] [Related]
5. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
7. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P; Kurscheid S; Delorenzi M; Gorlia T; van den Bent MJ; Hoang-Xuan K; Vauléon É; Gijtenbeek A; Enting R; Thiessen B; Chinot O; Dhermain F; Brandes AA; Reijneveld JC; Marosi C; Taphoorn MJB; Wick W; von Deimling A; French P; Stupp R; Baumert BG; Hegi ME
Acta Neuropathol; 2018 Apr; 135(4):601-615. PubMed ID: 29368212
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
9. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
10. Integrative analyses identify a DNA damage repair gene signature for prognosis prediction in lower grade gliomas.
Pang FM; Yan H; Mo JL; Li D; Chen Y; Zhang L; Liu ZQ; Zhou HH; Wu J; Li X
Future Oncol; 2020 Mar; 16(8):367-382. PubMed ID: 32065545
[No Abstract] [Full Text] [Related]
11. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma.
Meng X; Duan C; Pang H; Chen Q; Han B; Zha C; Dinislam M; Wu P; Li Z; Zhao S; Wang R; Lin L; Jiang C; Cai J
EBioMedicine; 2019 Mar; 41():185-199. PubMed ID: 30773478
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
14. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
15. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
16. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
17. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z
BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070
[TBL] [Abstract][Full Text] [Related]
18. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
Front Immunol; 2022; 13():982033. PubMed ID: 36052073
[TBL] [Abstract][Full Text] [Related]
19. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
